SCHEMBL11919930

SCHEMBL11919930

COc1ccc(-n2c(SCc3cc(C)on3)nnc2-c2ccncc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 8/20 0.67
TNKS O95271 5/20 0.67
MAPT P10636 4/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
THRB P10828 1/20 0.67
CYP3A4 P08684 2/20 0.64
CYP2C9 P11712 2/20 0.64
AXIN2 Q9Y2T1 2/20 0.64
CYP2D6 P10635 1/20 0.64
SULT2A1 Q06520 1/20 0.64
NR5A1 Q13285 1/20 0.64
TP53 P04637 5/20 0.61
NPSR1 Q6W5P4 3/20 0.53
USP2 O75604 2/20 0.53
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403463 0.80 CYP3A4 (0.73) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919898 0.78 TNKS2 (1.00) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL16010756 0.78 TNKS2 (1.00) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919928 0.78 TNKS2 (0.61) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919903 0.76 TP53 (1.00) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919912 0.76 TNKS2 (0.58) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919908 0.76 NPSR1 (0.90) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919927 0.76 TNKS2 (0.59) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919910 0.75 SMN1; SMN2 (0.84) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL6192012 0.74 ALPG (0.69) TNKS2TNKSMAPTSMN1; SMN2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TNKS2 1460/4885TNKS 1665/4885MAPT 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.